Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components (Tables)

v3.21.2
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Components of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,

2021

 

 

December 31,

2020

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

1,219

 

 

$

1,577

 

Clinical trial related costs

 

 

613

 

 

 

1,743

 

Non-clinical research and manufacturing operations

 

 

4,235

 

 

 

4,321

 

Payroll related

 

 

5,199

 

 

 

4,908

 

Other accrued expenses

 

 

39

 

 

 

26

 

Total Accrued liabilities

 

$

11,305

 

 

$

12,575